Day 1 - ET (Eastern Time, GMT-05:00)
- Christian Schubert - VP & Head, AbbVie Ventures, AbbVie
- Carolyn Ng - Partner & Manager Director, TPG Life Sciences
- Maha Radhakrishnan - Executive Partner, Sofinnova Investments
- Andrew Lam - Managing Director, Head of Biotech Private Equity, Ally Bridge Group
- Evan Rachlin - Co-Founder & Managing Partner, Ascenta Capital
- Björn Cochlovius - CEO, Eleva
- Willie Reaves - Chief of Staff, Cellino
- Sohail Zaidi - CEO, Ananda Scientific
- Reason . - CEO & Co-Founder, Repair Biotechnologies
- J.C. Lopez - Principal, NEA
- Maite Malet - Investment & Corporate Development, Asabys Partners
- Sourav Sinha - Partner, Bedford Bridge
- Dee Datta - Co-founder & CEO, Switch Therapeutics
- Andrew Parker - CEO, Step Pharma
- Rupert Haynes - CEO, Avata Biosciences
- Reetika Bhardwaj - Senior Associate, ARCH Venture Partners
- Fabio Pucci - Senior Director, Venture Investments, Leaps by Bayer
- Edgar Rodriguez - CEO, iOncologi
- Jennifer Lin - CEO, AUG Therapeutics
- Katja Vetvik - CEO, Thelper AS
- Madhusudan Peshwa - CEO, MKC Biotherapeutics
- Anshu Goyal - CEO, Xyone Therapeutics
- Alex Blyth - CEO, LIfT BioSciences
- Christian Howell - CEO, Cognito Therapeutics
- David Longo - CEO, Ordaos Bio
- Ashissh Raichura - CEO & Founder, Scanbo
- Nathalya Mamane - CEO, RT MicroDx
- John Erbey - CEO & Founder, Roivios
- Michael Rasche - CEO, Diadem
- Cody Simmons - CEO, DermaSensor
- Katerina Fialkovskaya - Investment Director, Philips Ventures
- Murielle Thinard McLane - President & Managing Partner, Intuitive Ventures
- Jonathan Machado - Managing Director, Samsung NEXT
- Jeffrey Weness - Head of Digital Investments, Otsuka Precision Health
- Niquette Hunt - Founder & CEO, Candesant Biomedical
The IPO Masterclass is designed specifically for biotech companies preparing to go public. This session will offer in-depth insights into the IPO process, tailored to the unique needs and challenges of life science innovators.
Led by seasoned industry experts, the masterclass will cover critical aspects of IPO preparation, including regulatory requirements, market timing, investor relations, and post-IPO strategies. Attendees will gain valuable knowledge on how to optimize their public offering, attract the right investors, and ensure long-term success in the public markets.
- Chris Downs - CFO, CNS Pharma
- Bernard Peperstraete - Founder & CEO, AcuamarkDx
- Jason Sieger - COO, Innovacell
- Stephanie Bewick - CBO, Accession Therapeutics
The Licensing Masterclass is a targeted session designed for biotech companies seeking to forge licensing deals with pharma partners. This masterclass will provide expert guidance on the strategic, financial, and legal aspects of licensing agreements, helping biotech innovators maximize the value of their assets.
Industry veterans will share best practices for identifying and negotiating with potential pharma partners, structuring deals, protecting intellectual property, and navigating the complexities of licensing contracts. Attendees will leave with a clear understanding of how to secure partnerships that drive growth and commercialization of their biotech innovations.
- Mikko Turunen - Founder & CSO, RNatives Inc.
- Justin Vogel - CFO, Tolerance Bio
- Anita Davidson - President & CEO, Creative Biotherapeutics
- Tiffany Brown - CEO, Avobis
- Bin Wu - Founder & CEO, Cytodigm
- Ramon Mohanlal - CEO, RND Pharmaceuticals
- Sanjay Shrivastava - CEO, Innova Vascular
- Dan Gladney - CEO, AriaCV
- Christopher Prentice - CCO, LEM Surgical
- Christine Horton - CEO, Visura
- Ben Casavant - Co-Founder & CEO, Tasso
- Luis Alvarez - CEO, Theradaptive
The M&A Masterclass is tailored for life sciences start-ups aiming to explore M&A opportunities and best practices with larger strategic companies. This session offers strategic insights into the M&A process, equipping emerging biotech and medtech companies with the knowledge to successfully navigate these transformative deals.
Led by experienced M&A professionals, the masterclass will cover key topics such as valuation, deal structuring, due diligence, and post-merger integration. Attendees will learn how to position their companies as attractive acquisition targets, negotiate favorable terms, and align with the strategic goals of large pharma partners.
- Jim MacKrell - VP Lilly Venture Science, Eli Lilly
- James Buxton - Principal, NEA
- John Boyce - Managing Director & Co-Founder, TigerGene
- Mahesh Narayanan - Managing Partner, Neuvation Ventures
- Eric Snyder - Partner, Venture Investments, Novo Holdings